Accuray reports Q4 EPS 3c, consensus 3c

Reports Q4 revenue $134.3M, consensus $121.51M. “Our team finished the year with a solid Q4 performance closing several opportunities that were open from the prior period. We secured new product approvals and significant customer wins, and initiated sales in new markets. These achievements and more have enabled us to establish a strong foundation from which to grow our global business in the years ahead,” said Suzanne Winter, CEO. “As we look to FY25, we will continue to focus our investments on innovations driven by the voice of our customers. We remain confident in our ability to provide clinical teams worldwide with a product portfolio that enables them to elevate cancer care both today and into the future.”